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The presence or absence of oestrogen receptor
protein in human breast cancer is now well estab-
lished as an index for predicting response to
hormonal therapy and as an independent
prognostic factor (Jensen, 1975; Hawkins et al.,
1980). Additional assessment of progesterone
receptor activity has been reported to increase
further the accuracy of selecting patients for
hormonal therapy (Horrowitz et al., 1975; Knight
et al., 1980). More recently, studies of rat
mammary tumours have shown that there seems to
be an antagonistic action between oestrogen
receptor activity and cyclic AMP binding proteins
(subunits of the enzyme protein kinase) such that
hormone-dependent tumours have high oestrogen
receptor and low cyclic AMP-binding activities
(Cho-Chung et al., 1978). Preliminary studies
indicate that this activity also may be of prognostic
significance in human breast cancers (Miller et al.,
1983).
Breast cancers are heterogeneous in both
morphology and function: they often show
considerable variations in, for example, oestrogen
receptor activity across the tumour (Braunsberg,
1975; Hawkins et al., 1977; Silfversward et al.,
1980) which could be due to variations in malig-
nant epithelial cell content, to the presence of two
or more populations of malignant epithelial cells
(McCormack, 1984), or to differences in cell
viability or function.
In the present study, we have examined the
variations in the levels of oestrogen receptor,
progesterone receptor and cyclic AMP binding
proteins which may occur across large, primary
breast cancers.
The tumours from each of 12 patients presenting
with a large primary cancer of the breast were
collected at mastectomy. The patients ranged in age
from 49 to 92 years, eleven being postmenopausal
and one premenopausal. The tumours were staged
as T2 (three), T3 (four), or T4 (five).
At mastectomy the breast was placed on ice and
the entire tumour was excised. This was cut up
carefully in a cold room by a method based on that
of Silfversward et al. (1980), to yield samples from
the tumour periphery (P), from the tumour centre
(C), and from the area intermediate between those
two (M). A thin slice across the face of each
portion was taken and fixed in formol-saline,
processed routinely and stained with haematoxylin
and eosin. The sections were later examined for
tumour cellularity (scored as an estimate of the
percentage of tissue occupied by tumour cells), the
degree of pleomorphism, differentiation, presence of
local necrosis, and degree of lymphocytic
infiltration. The remainder of each tumour portion
was used for the measurement of oestrogen receptor
activity, progesterone receptor activity and cyclic
AMP binding by methods (Miller et al. 1985;
Hawkins et al., 1975; Hawkins et al., 1981) used
previously, the assays for steroid receptors being
slightly modified by the use of the buffer required
for cyclic AMP binding assay (Miller et al., 1985),
a high speed supernatant and delayed addition of
monothioglycerol. These changes did not influence
the steroid receptor values. For each assay the data
were analysed according to Scatchard (1949).
The total soluble protein concentration in each
cytosol was determined by the dye-binding method
of Bradford (1976), and the DNA content of the
nuclear pellet was determined by a modification of
the method of Burton (1956).
In an essential preliminary investigation, the
extent of variations due to the analytical method
used, was determined by dividing a large tumour as
finely as possible, mixing and redividing it into 5
portions for assay. The resulting intra-assay
precisions are shown in Table I.
For each of the 12 selected tumours, the P, C
and M portions were examined histologically. There
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Table I The intraassay precision of measurements of
oestrogen receptor, progestogen receptor, and cyclic AMP-
binding protein concentrationsa
Concentration
Cv
Binding protein Mean+ s.d. (%)
Oestrogen receptor
fmimg-1 wet wt 1.09+0.13 12.1
fmmg-' cytosol protein 31.6+3.6 11.4
fmpg'- DNA 0.30+0.020 6.7
Progestogen receptor
fmmg- 1 wet wt 3.36+0.29 8.6
fmmg ' cytosol protein 97.5+7.6 7.8
fmpg'-l DNA 0.92+0.068 7.4
Cyclic AMP-binding protein
fmmg- 1 wet wt 47.4 +4.69 9.9
fmmg-1 cytosol protein 1380+ 110 7.9
fmpg-1 DNA 13.1+1.61 12.3
'A large breast cancer was cut up finely, mixed and
divided into 5 portions: each portion was assayed for the
three binding proteins, total soluble protein concentration
of the cytosol and for DNA in the tissue pellet.
was little or no variation in the degree of pleo-
morphism, differentiation, necrosis and extent of
lymphocytic infiltration across the tumours. In
contrast, variations in cellularity were apparent in 7
tumours with a trend for increasing cellularity score
from centre to periphery, the remaining five
tumours showing little variation. On average, the
cellularity in the C and M zones were 66 and 87%
respectively of those seeen in the peripheral zone
(100%).
When the three portions from each of the 12
tumours were examined biochemically, the pellet
DNA content and steroid receptor concentrations
on a wet weight basis, were significantly lower in
the C and M zones than in the periphery (Table II).
By contrast, soluble protein concentration and
cyclic AMP binding activity did not significantly
change from centre to periphery.
With a view to eliminating the effect of variations
in tumour cellularity on the apparent changes in
concentration of each binding protein, the relation-
ships of cellularity to (a) soluble protein concen-
tration (mgml - 1 cytosol) and (b) pellet DNA
content (pgmg- 1 tumour) were examined. The
results showed that in each tumour zone, the
estimates of tumour cellularity were strongly
correlated with pellet DNA content (P<0.001,
P <0.001, P<0.05 for the C, M and P zones
respectively, by linear regression analysis), but only
weakly related to soluble protein concentration
(P=NS, P<0.05, P=NS for the C, M and P zones
respectively). DNA content is thus a good index of
cellularity and expression of the three binding
protein activities on this basis may be expected to
eliminate the influence of cellularity. Even on this
basis, significant variations in binding activity
Table II The variations in biochemical parameters and cellularity across a tumour in
twelve patients with breast cancer
Mean valuea Relative valuesb
Parameter (P) P M C
Cellularity (%) 38 1.00 0.87** 0.66**
Soluble protein 3.34 1.00 0.97 0.93
(mgml-1 cytosol)
Pellet DNA 3.68 1.00 0.95 0.78*
(pgmg-' tumour)
Oestrogen receptor 7.99 1.00 0.78 0.56***
activity (fmolmg-1 tumour)
Progestogen receptor 4.19 1.00 0.72*** 0.32*
activity (fmolmg-1 tumour)
Cyclic AMP binding 153 1.00 1.02 1.07
(fmolmg-1 tumour)
aMean value found in the peripheral zones (P) of the 12 tumours; bWithin each
tumour, values in the central (C) and intermediate (M) zones were expressed as a
fraction of the value found in the peripheral zone (P): 'relative value' represents the
mean of the fractions found in the 12 tumours. For OeR, n=11 only (1 tumour
negative). For PgR, n=7 only (5 tumours were all negative).
*P<0 05)
**P<0.02 by comparison with peripheral portion (paired Wilcoxon Rank test)
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across the tumours remained (Figure 1). While on
average, the concentrations of the steroid receptor
activities fell from periphery to centre, the reverse
change was seen in cyclic AMP binding activity.
For the steroid receptor activities, these changes
were apparent irrespective of the way in which
concentrations were expressed (i.e. mg-1 wet
weight, mg-1 protein or g-1 DNA): for cyclic
AMP binding activity, the difference was only
apparent on a DNA basis.
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Figure 1 The inverse changes in steroid receptor
concentrations (OeR *---0 and PgR 0-0) and
cyclic AMP-binding protein A-A across 12 large
breast cancers. Each point represents the mean value
for a given zone from the 12 tumours (C=central,
M =intermediate, P=peripheral), expressed on a DNA
basis.
To our knowledge, this is the first report of the
simultaneous measurement of the concentrations of
these three high affinity binding proteins across a
tumour. Trans-tumoral variations in binding
protein concentration might derive from at least 3
sources: variations in malignant epithelial
cells/stroma ratio ('cellularity'), the existence of 2 or
more cell populations, or variations in cell
viability/function. In agreement with an earlier
study (Mason et al., 1982), DNA content of the
tumour was found to be a good index of cellularity,
yet even after expression of results on a DNA basis,
significant trans-tumoural variations in the concen-
trations of binding protein remained. It is therefore
unlikely that these variations are due to changes in
cellularity. Differences in cell type across a tumour
could explain the present findings. Although
previous studies have demonstrated an inverse
correlation between oestrogen receptor activity and
lymphocytic infiltration (Rosen et al., 1975) or
tumour macrophage content (Steele et al., 1986)
between tumours, no obvious differences in
lymphocytic infiltration were observed here.
However, since macrophages are not easily distin-
guished from tumour cells in the breast (Steele et
al., 1986), the possibility remains that the propor-
tion of each cell type varies across a large tumour.
In our view, it seems most likely that the trans-
tumoural variations reside in differences in the
viability/function of the malignant epithelial cell
populations. Large tumours might be expected to
be less well vascularised in the centre than at the
periphery which could perhaps ultimately lead to
central necrosis, but histologically there were no
gross differences to provide evidence for such a
chronic, non-specific effect on cell viability. It may
be, however, that there are acute, more specific
changes across a tumour. These may be similar to
the rapid, inverse changes in cyclic AMP binding
activity and oestrogen receptor concentration which
occur during the regression of hormone-dependent
mammary tumours in the rat (Cho-Chung et al.,
1978).
It is concluded that in a large breast cancer, since
both cyclic AMP binding and oestrogen receptor
activity are indices of hormonal sensitivity
(Kvinnsland et al., 1983; Watson et al., 1986), (1) it
may be important to assay the entire tumour or
sample all zones for the assessment of binding
protein concentrations and (2) transtumoural
variations in binding protein activity may be a
reflection of differences in biological behaviour
between the centre and periphery.
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